Agios Pharmaceuticals, Inc. (AGIO)
33.32
-0.96
(-2.80%)
USD |
NASDAQ |
Aug 28, 16:00
33.32
0.00 (0.00%)
After-Hours: 20:00
Agios Pharmaceuticals Free Cash Flow : -365.25M for June 30, 2026
Free Cash Flow Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | -365.25M |
| March 31, 2026 | -384.73M |
| December 31, 2025 | -377.29M |
| September 30, 2025 | -414.09M |
| June 30, 2025 | -409.02M |
| March 31, 2025 | -403.77M |
| December 31, 2024 | -391.53M |
| September 30, 2024 | -330.11M |
| June 30, 2024 | -307.49M |
| March 31, 2024 | -301.49M |
| December 31, 2023 | -297.06M |
| September 30, 2023 | -290.62M |
| June 30, 2023 | -299.99M |
| March 31, 2023 | -309.40M |
| December 31, 2022 | -314.36M |
| September 30, 2022 | -336.68M |
| June 30, 2022 | -350.45M |
| March 31, 2022 | -391.84M |
| December 31, 2021 | -413.06M |
| September 30, 2021 | -374.42M |
| June 30, 2021 | -362.67M |
| March 31, 2021 | -317.07M |
| December 31, 2020 | -304.86M |
| September 30, 2020 | -355.34M |
| June 30, 2020 | -369.56M |
| Date | Value |
|---|---|
| March 31, 2020 | -387.04M |
| December 31, 2019 | -382.79M |
| September 30, 2019 | -357.60M |
| June 30, 2019 | -336.95M |
| March 31, 2019 | -316.28M |
| December 31, 2018 | -311.41M |
| September 30, 2018 | -311.90M |
| June 30, 2018 | -324.66M |
| March 31, 2018 | -315.92M |
| December 31, 2017 | -289.86M |
| September 30, 2017 | -266.57M |
| June 30, 2017 | -239.29M |
| March 31, 2017 | -24.18M |
| December 31, 2016 | 28.65M |
| September 30, 2016 | 48.38M |
| June 30, 2016 | 72.72M |
| March 31, 2016 | -89.27M |
| December 31, 2015 | -97.11M |
| September 30, 2015 | -73.66M |
| June 30, 2015 | -69.64M |
| March 31, 2015 | -63.90M |
| December 31, 2014 | -61.57M |
| September 30, 2014 | -66.14M |
| June 30, 2014 | -57.12M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| ACADIA Pharmaceuticals, Inc. | 145.62M |
| Biogen, Inc. | 2.49B |
| Insmed, Inc. | -837.67M |
| Alnylam Pharmaceuticals, Inc. | 793.94M |
| Exelixis, Inc. | 1.172B |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -57.31M |
| Cash from Investing (Quarterly) | 40.21M |
| Cash from Financing (Quarterly) | 3.149M |
| Free Cash Flow Per Share (Quarterly) | -0.9838 |
| Free Cash Flow to Equity (Quarterly) | -53.95M |
| Free Cash Flow to Firm (Quarterly) | -58.52M |
| Free Cash Flow Yield | -18.68% |